Breaking News Instant updates and real-time market news.

AKRX

Akorn

$33.10

0.015 (0.05%)

, ALIM

Alimera Sciences

$1.45

-0.08 (-5.23%)

04:55
05/09/17
05/09
04:55
05/09/17
04:55

American Society of Cataract & Refractive Surgery to hold annual meeting

2017 Annual Meeting of ASCRS is being held in Los Angeles on May 5-9.

AKRX

Akorn

$33.10

0.015 (0.05%)

ALIM

Alimera Sciences

$1.45

-0.08 (-5.23%)

AGN

Allergan

$241.95

-2.99 (-1.22%)

IRIX

IRIDEX

$9.67

0.045 (0.47%)

JNJ

Johnson & Johnson

$123.25

-0.26 (-0.21%)

NBY

NovaBay

$2.90

(0.00%)

NVS

Novartis

$77.90

0.08 (0.10%)

OCUL

Ocular Therapeutix

$8.07

0.44 (5.77%)

OMER

Omeros

$15.43

0.07 (0.46%)

RTRX

Retrophin

$17.26

-0.66 (-3.68%)

SHPG

Shire

$176.96

-4.65 (-2.56%)

STAA

STAAR Surgical

$10.10

(0.00%)

TEAR

TearLab

$1.95

-0.14 (-6.70%)

  • 09

    May

  • 09

    May

  • 09

    May

  • 10

    May

  • 11

    May

  • 15

    May

  • 16

    May

  • 16

    May

  • 17

    May

  • 22

    May

  • 31

    May

  • 06

    Jun

  • 14

    Jun

  • 26

    Jun

  • 19

    Jul

AKRX Akorn
$33.10

0.015 (0.05%)

04/25/17
04/25/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Amazon.com (AMZN) downgraded to Market Perform from Outperform at Raymond James with analyst Aaron Kessler saying the shares are fairly valued after rallying 21% this year and 44% over the last 12 months. The analyst expects Amazon's investment levels to remain elevated in the near-term and he views consensus operating income estimates for the second quarter as aggressive. 2. General Electric (GE) downgraded to Neutral from Buy at BofA/Merrill with analyst Andrew Obin saying he sees headwinds from weaker Oil & Gas margin, Healthcare, and Power and reduced estimates below consensus. 3. Conagra Brands (CAG) downgraded to Sell from Neutral at UBS with analyst Steven Strycula citing expectations the stock's relative valuation premium will contract amid a decelerating rate of margin improvement and "limited room" for positive earnings estimate revisions. Conagra's portfolio is not well positioned for a consolidating merchandise set, the analyst contends. He cut his price target for the shares to $35 from $38. 4. NGL Energy Partners (NGL) downgraded to Market Perform from Outperform at FBR Capital with analyst Robert Balsamo saying the company's guidance reflects underappreciated risks to its cash flows. 5. Akorn (AKRX) was downgraded to Hold from Buy at Jefferies and Craig-Hallum, to Market Perform from Outperform at William Blair, and to Neutral from Overweight at Piper Jaffray. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/25/17
WBLR
04/25/17
DOWNGRADE
WBLR
Market Perform
Akorn downgraded to Market Perform from Outperform at William Blair
William Blair analyst Tim Lugo downgraded Akorn to Market Perform saying that while the price paid by Fresenius Kabi was below his $36-$48 per share expectation, the buyout agreement "represents reasonable value" for long-term shareholders. The analyst believes the transaction will likely close at the negotiated price.
04/25/17
CHLM
04/25/17
DOWNGRADE
Target $34
CHLM
Hold
Akorn downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum analyst Matt Hewitt downgraded Akorn (AKRX) to Hold from Buy, with a $34 price target, after the announcement that it has agreed to sell the company to Fresenius (FSNUY) for $34 per share in cash and the assumption of about $450M in debt. While the analyst would have liked to have seen Akorn sell for more, the deal still creates "significant value" for many shareholders and is a strategically complementary marriage that makes sense for both sides.
04/25/17
JEFF
04/25/17
DOWNGRADE
Target $34
JEFF
Hold
Akorn downgraded to Hold from Buy at Jefferies
Jefferies analyst David Steinberg downgraded Akorn (AKRX) to Hold citing a low probability of competitive takeover bids since the story of the deal talks broke 17 days ago. The analyst raised his price target for Akorn shares to $34 to reflect the Fresenius (FSNUY) buyout agreement.
ALIM Alimera Sciences
$1.45

-0.08 (-5.23%)

09/16/16
COWN
09/16/16
UPGRADE
Target $3
COWN
Outperform
Alimera Sciences upgraded to Outperform from Market Perform at Cowen
Cowen analyst Boris Peaker upgraded Alimera Sciences to Outperform and established a $3 price target. The analyst believes the recent refinancing removes an overhang as the company is now capitalized to comfortably reach cash-flow breakeven next year and not at risk of tripping its debt covenants. Further, Peaker sees significant room for upside from Iluvien sales growth.
04/27/17
RODM
04/27/17
INITIATION
Target $4
RODM
Buy
Alimera Sciences initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Raghuram Selvaraju started Alimera Sciences with a Buy rating and $4 price target. The analyst believes the company's commercialized product, Iluvien, is differentiated from other corticosteroid treatment options for diabetic macular edema.
AGN Allergan
$241.95

-2.99 (-1.22%)

04/06/17
OPCO
04/06/17
NO CHANGE
Target $43
OPCO
Outperform
Teva Austedo approval 'a nice incremental positive,' says Oppenheimer
Oppenheimer analyst Derek Archila notes that Teva (TEVA) received approval for Austedo for Huntington's chorea, which he sees as "a nice positive" given the company's recent challenges. Based on his review of the label and recent physician checks, the analyst believes Austedo could potentially become first-line therapy for Huntington's chorea and forecasts sales of about $600M by 2022 in this indication. Archila continues to like Teva's shares long term, though he expects they may be range-bound until a new CEO is hired, generic business stabilizes, and Allergan's (AGN) stake in Teva is resolved. He reiterates an Outperform rating and $43 price target on Teva's shares.
04/21/17
SBSH
04/21/17
NO CHANGE
Target $270
SBSH
Buy
Allergan removed from U.S. Focus List at Citi
Citi analyst Liav Abraham removed Allergan from her firm's U.S. Focus List citing the rally in the shares since late 2016. The analyst, however, keeps a buy rating on Allergan and upped her price target for the stock to $270 from $245. Evidence of execution on key pipeline assets is likely required for further share upside, Abraham tells investors in a research note.
04/18/17
WELS
04/18/17
NO CHANGE
WELS
Allergan partnership a 'promising free option,' says Wells Fargo
Wells Fargo analyst David Maris views Allergan's (AGN) partnership with Novartis (NVS) to conduct a Phase IIb study using its cenicriviroc and Novartis's lead FXR agonist for the treatment of nonalcoholic steatohepatitis as a "promising free option." The deal is a way to maximize Allergan's shots-on-goal in combination NASH treatments, Maris tells investors in a research note. He has an Outperform rating on Allergan shares.
04/06/17
WELS
04/06/17
NO CHANGE
WELS
Allergan Botox data shows potential efficacy in depression, says Wells Fargo
Wells Fargo says that Phase II data on Allergan's Botox as a treatment for depression was mixed but indicated that the drug could have efficacy as a depression treatment. The firm says that investors could soon start to view Botox for depression as "another legitimate large shot on goal" for Allergan. Wells keeps an Outperform rating on the shares.
IRIX IRIDEX
$9.67

0.045 (0.47%)

12/21/16
ROTH
12/21/16
INITIATION
Target $20
ROTH
Buy
IRIDEX initiated with a Buy at Roth Capital
Roth Capital analyst Chris Lewis started IRIDEX with a Buy rating and $20 price target as he believes the company is in the early stages of a meaningful value driver with its G6 MicroPulse platform for glaucoma that the analyst expects should accelerate top-line growth and expand gross margins over the coming years.
JNJ Johnson & Johnson
$123.25

-0.26 (-0.21%)

04/24/17
BARD
04/24/17
NO CHANGE
Target $5
BARD
Outperform
Achillion price target lowered to $5 from $10 at Baird
Baird analyst Brian Skorney lowered his price target on Achillion (ACHN) to $5 from $10 on its disappointing Hep-C results, which indicated a weakness when it comes to genotype 3 patients. Although he expects partner Johnson & Johnson (JNJ) to push the trial into Phase 3, he think it makes the regimen a more difficult sell with other drugs offering genotype 3 efficacy. Skorney maintained his Outperform rating on Achillion shares.
04/25/17
JMPS
04/25/17
NO CHANGE
JMPS
Johsnson &Johnson data positive for Achillion, says JMP Securities
JMP Securities analyst Liisa Bayko says that data on a triple combination HCV treatment presented by Johnson & Johnson (JNJ) yesterday is positive for Achillion (ACHN). The analyst noted that the triple combination includes Achillion's odalasvir and that the six week treatment regimen is shorter than the eight weeks required for Gilead's (GILD) Harvoni. The analyst says that Achillion's stock dropped sharply yesterday because there was disappointment over the combination's efficacy in genotype 3 patients. However, she says that such patients only represent 10% of the total, and she says that Achillion can "conservatively" obtain peak royalty revenue of about $100M from its drug. Bayko keeps a $13 price target and an Outperform rating on the shares.
04/25/17
MAXM
04/25/17
NO CHANGE
Target $5
MAXM
Buy
Achillion price target lowered to $5 from $8 at Maxim
Maxim analyst Jason Kolbert said phase 2 trial results demonstrated that Achillion's (ACHN) triple combination of simeprevir, odalasvir and AL-335 has the ability to shorten treatment duration, be generally well tolerated and offer high efficacy for hepatitis C virus genotype 1 patients. While Johnson & Johnson (JNJ) is likely to move forward with this regimen, allowing Achillion to realize milestones, Kolbert has removed any royalties from his model as he expects others to dominate the landscape with "near perfect" regimens. Kolbert lowered his price target on Achillion to $5 from $8 but keeps a Buy rating on the shares.
04/19/17
LEER
04/19/17
NO CHANGE
Target $140
LEER
Outperform
Johnson & Johnson price target lowered to $140 from $150 at Leerink
Leerink analyst Danielle Antalffy lowered her price target for Johnson & Johnson to $140 from $150 on valuation. The analyst notes that the shares sold off as investors seemed taken aback by weakness in both non-REMICADE Pharma and Consumer, but he points out that there are a number of potential drivers of an improving outlook going forward, including Medical Devices growth reacceleration, continued strong double-digit growth of key new drugs, and likely consumer growth reacceleration as the macroeconomic environment improves and with consumer confidence at its highest level in years. The analyst reiterates an Outperform rating on the shares.
NBY NovaBay
$2.90

(0.00%)

02/06/17
RODM
02/06/17
INITIATION
Target $6
RODM
Buy
NovaBay initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Raghuram Selvaraju started NovaBay Pharmaceuticals with a Buy rating and $6 price target. The company's risk is mitigated given its "high-growth lead franchise," or Avenova, an eyelid and eyelash cleaner for treatment of blepharitis and dry eye disease, Selvaraju tells investors in a research note.
03/28/17
LDLW
03/28/17
INITIATION
Target $10
LDLW
Buy
NovaBay initiated with a Buy at Laidlaw
Laidlaw analyst Jim Molloy initiated NovaBay with a Buy and a $10 price target saying it represents an exciting turnaround story since their new CEO Mark Sieczkarek transformed their commercial strategy at the beginning of 2016 from a buy and bill sales model to focusing on prescription sales through ophthalmologists. While NovaBay is solely focusing on U.S. Avenova sales for the moment, the approximately $30M recurring patients with blepharitis and dry eye alone attests to the impressive size of the market opportunity, the analyst wrote.
NVS Novartis
$77.90

0.08 (0.10%)

04/21/17
ROTH
04/21/17
NO CHANGE
Target $12
ROTH
Buy
Conatus price target raised to $12 from $4 at Roth Capital
Roth Capital analyst Sa'ar Yaniv raised his price target for Conatus (CNAT) to $12 from $4 following discussions with management, 2016 results, assessment of the competitive cirrhosis space, and clarity from the Novartis (NVS) deal. The analyst believes Conatus' shares are undervalued and reiterates a Buy rating on the stock.
04/05/17
COWN
04/05/17
DOWNGRADE
Target $77
COWN
Market Perform
Novartis downgraded to Market Perform from Outperform at Cowen
Cowen analyst Steve Scala downgraded Novartis to Market Perform and lowered his price target for the shares to $77 from $87. The analyst believes the company's earnings growth looks below the industry average given the current weakness in Alcon and Entresto's slow rollout.
04/05/17
04/05/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) downgraded to Neutral from Buy at UBS. 2. Novartis (NVS) downgraded to Market Perform from Outperform at Cowen with analyst Steve Scala saying he believes the company's earnings growth looks below the industry average given the current weakness in Alcon and Entresto's slow rollout. 3. MSG Networks (MSGN) downgraded to Neutral following NY Post report at Macquarie with analyst Tim Nollen citing valuation and maintained its $26 price target. 4. Generac (GNRC) downgraded to Sector Weight from Overweight at KeyBanc with analyst Jeffrey Hammond citing concerns that increased pricing incentives and normalizing storm activity are impacting the growth for the company's Residential home standby business. 5. Amgen (AMGN) downgraded to Hold from Buy at Jefferies with analyst Eun Yang saying she believes upside in the stock will likely be "muted" after her payor poll indicated continuing reimbursement challenges for Repatha, Amgen's PCSK9 inhibitor to treat high cholesterol. Yang also sees a "scarcity of blockbuster potential pipeline products" and feels a transformative acquisition is unlikely. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
OCUL Ocular Therapeutix
$8.07

0.44 (5.77%)

05/05/17
BTIG
05/05/17
DOWNGRADE
BTIG
Neutral
Ocular Therapeutix downgraded to Neutral from Buy at BTIG
05/05/17
05/05/17
DOWNGRADE

Neutral
Ocular Therapeutix downgraded to Neutral on risk of Dextenza delay at BTIG
As previously reported, BTIG analyst Dane Leone downgraded Ocular Therapeutix to Neutral from Buy citing risk of a delay for the current PDUFA date for Dextenza following the issuance of another Form 483, which the FDA issued following a site re-inspection. The current PDUFA action date for Dextenza is July 19 and a delayed launch would "materially" affect estimates, Leone noted.
02/10/17
02/10/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Symantec (SYMC) reinstated with an Equal Weight at Barclays. 2. Discovery (DISCA) and AMC Networks (AMCX) were initiated with a Hold at Deutsche Bank. 3. Ocular Therapeutix (OCUL) initiated with an Overweight at Cantor. 4. MarineMax (HZO) initiated with a Buy at Citi. 5. Williams Partners (WPZ) was initiated with a Buy at Deutsche Bank, while Williams (WMB) was initiated with a Hold. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/09/17
CANT
02/09/17
INITIATION
Target $35
CANT
Overweight
Ocular Therapeutix initiated with an Overweight at Cantor
Cantor initiated Ocular Therapeutix with an Overweight and a $35 price target.
OMER Omeros
$15.43

0.07 (0.46%)

06/02/16
CANT
06/02/16
INITIATION
Target $21
CANT
Buy
Omeros initiated with a Buy at Cantor
Target $21.
RTRX Retrophin
$17.26

-0.66 (-3.68%)

11/21/16
BMOC
11/21/16
NO CHANGE
BMOC
Retrophin price target raised to $46 from $40 at BMO Capital
BMO Capital analyst Do Kim raised the price target on Retrophin after the company provided data on its Sparsentan treatment that the analyst views as positive. Kim now sees a 55% chance that the drug will be approved, up from 45% previously. The analyst continues to believe that the FDA might not accept proteinuria as an endpoint, but sees "growing evidence for proteinuria as a surrogate to kidney survival." Kim keeps an Outperform rating on the stock.
04/06/17
WBLR
04/06/17
INITIATION
WBLR
Outperform
Retrophin initiated with an Outperform at William Blair
William Blair analyst Tim Lugo started Retrophin with an Outperform rating on expectations the company will transition from a "poster child for controversial pricing practices to a pipeline execution story."
11/21/16
LEER
11/21/16
NO CHANGE
LEER
Outperform
Retrophin DUET data reintroduces accelerated approval optionality, says Leerink
Leerink analyst Joseph Schwartz says full DUET Phase 2b results for Retrophin's sparsentan in focal segmental glomerulosclerosis presented at the American Society of Nephrology Kidney Week meeting look "very strong" in terms of the ability of the drug to produce modified partial remissions and even some complete remissions during the 8-week double blind period. The analyst believes the "strong data" provides the company with as good an argument as ever to discuss the potential of accelerated approval with the FDA, although he notes that predicting FDA is "tough." He reiterates an Outperform rating on the shares.
12/15/16
JMPS
12/15/16
NO CHANGE
JMPS
Experts support quick approval of Retrophin sparsentan, says JMP Securities
JMP Securities analyst Liisa Bayko says the firm's survey of experts who participated in the Phase 2 study of Retrophin's sparsentan in focal segmental glomerulosclerosis "showed strong support for accelerated approval" of the drug. Bayko reiterates a $28 price target and an Outperform rating on the shares of Retrophin.
SHPG Shire
$176.96

-4.65 (-2.56%)

01/19/17
01/19/17
NO CHANGE

Shire's application for ADHD disorder candidate acknowledged by FDA
Shire announced that the FDA has acknowledged receipt of the Class 2 resubmission of a New Drug Application for SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation. SHP465 is being evaluated as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder. The FDA is expected to provide a decision on or around June 20. Shire resubmitted the NDA for SHP465 in response to the Approvable Letter from the FDA that requested additional clinical studies and classified the response as a Class 2 resubmission with a review goal of six months. Launch is planned for the second half of 2017.
03/07/17
LEHM
03/07/17
NO CHANGE
LEHM
European Pharma raised to Positive from Neutral at Barclays
Barclays analyst Emmanuel Papadakis rolled out coverage of the European Pharmaceuticals space and upgraded his sector view to Positive from Neutral. The analyst has "high conviction that the recent transformational era of R&D innovation is set to continue," which he believes will allow the sector to retain pricing power. Papadakis put Overweight ratings on AstraZeneca (AZN), Roche (RHHBY) and Shire (SHPG), with Astra his top pick. The analyst put an Equal Weight rating on GlaxoSmithKline (GSK) and Underweight ratings on Sanofi (SNY), Novartis (NVS) and Novo Nordisk (NVO).
04/10/17
STFL
04/10/17
NO CHANGE
STFL
Shire new HAE drug likely to be momentum driver, says Stifel
Stifel analyst Annabel Samimy says that there is a high probability that Shire's SHP643, a SubQ, once- or twice-monthly prophylactic treatment for hereditary angioedema, will be successful, as the analyst says that the drug would "present a meaningful advance to current prophylactic treatment" of the disease. The analyst thinks that the treatment could expand the market for prophylaxis, as the current standard of care is administered through IV, and she expects it to create momentum for Shire's stock. Samimy notes that Phase 3 data on the drug is expected to be released soon. She keeps a $250 price target and a Buy rating on the shares.
03/07/17
LEHM
03/07/17
INITIATION
LEHM
Overweight
Shire reinstated with an Overweight at Barclays
After his firm dropped coverage in June 2016, Barclays analyst Emmanuel Papadakis reinstated Shire with an Overweight rating and GBP 65 price target. The rating is unchanged from last year.
STAA STAAR Surgical
$10.10

(0.00%)

05/12/16
SPHN
05/12/16
DOWNGRADE
Target $8
SPHN
Equal Weight
STAAR Surgical downgraded to Equal Weight from Overweight at Stephens
Stephens analyst Chris Cooley downgraded STAAR Surgical to Equal Weight from Overweight as he believes the shares will remain range-bound in the near-term barring a favorable resolution of FDA remediation efforts and more clarity on its revised cataract franchise strategy. The analyst lowered his price target on the stock to $8 from $10.
TEAR TearLab
$1.95

-0.14 (-6.70%)

03/10/17
CHLM
03/10/17
NO CHANGE
Target $5.5
CHLM
Buy
TearLab price target lowered to $5.50 from $15 at Craig-Hallum
Craig-Hallum analyst Bill Bonello lowered his price target for TearLab to $5.50 from $15, citing near-term challenges and a lack of visibility. While the analyst continues to believe that TearLab has a compelling solution for the diagnosis of dry eye disease, and the potential to expand its platform to other eye conditions and potentially beyond, challenges persist. He reiterates a Buy rating on the shares.
03/10/17
FLTL
03/10/17
DOWNGRADE
Target $8.5
FLTL
Buy
TearLab downgraded to Buy from Strong Buy at Feltl
Feltl analyst Ben Haynor downgraded TearLab to Buy from Strong Buy citing a lower multiple and implied growth rate following the company's Q4 results. The analyst cut his price target for the shares to $8.50 from $20.
08/04/16
ROTH
08/04/16
DOWNGRADE
Target $0.9
ROTH
Neutral
TearLab downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Chris Lewis downgraded TearLab to Neutral from Buy as light Q2 year over year growth of 9% and lowered 2016 outlook increases concerns around the company's growth deceleration, sales visibility, slowing new net placements/higher attrition rates, and declining MASTERS utilization trends. The analyst also lowered his price target on the shares to 90c from $1.25.
03/13/17
ROTH
03/13/17
NO CHANGE
Target $4.5
ROTH
Neutral
TearLab price target lowered to $4.50 from $7 at Roth Capital
Roth Capital analyst Chris Lewis lowered his price target for TearLab to $4.50 from $7 given the continued growth deceleration and lack of sales visibility. The analyst reiterates a Neutral rating on the shares.

TODAY'S FREE FLY STORIES

CBS

CBS

$51.75

0.14 (0.27%)

21:20
05/20/18
05/20
21:20
05/20/18
21:20
Upgrade
CBS rating change at Bernstein »

CBS upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNX

Knight-Swift

$40.63

0.89 (2.24%)

20:40
05/20/18
05/20
20:40
05/20/18
20:40
Upgrade
Knight-Swift rating change at Stifel »

Knight-Swift upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

FOX

21st Century Fox

$37.27

-0.01 (-0.03%)

, FOXA

21st Century Fox

$37.67

-0.08 (-0.21%)

19:24
05/20/18
05/20
19:24
05/20/18
19:24
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

FOX

21st Century Fox

$37.27

-0.01 (-0.03%)

FOXA

21st Century Fox

$37.67

-0.08 (-0.21%)

PG

Procter & Gamble

$73.45

-0.51 (-0.69%)

PEP

PepsiCo

$97.51

-0.45 (-0.46%)

KO

Coca-Cola

$42.18

-0.13 (-0.31%)

CBS

CBS

$51.75

0.14 (0.27%)

ROKU

Roku

$35.40

1.14 (3.33%)

LOW

Lowe's

$86.31

0.85 (0.99%)

GE

General Electric

$14.98

-0.05 (-0.33%)

WAB

Wabtec

$95.23

1.1 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 22

    May

  • 23

    May

  • 12

    Jun

JHG

Janus Henderson Group

$32.43

-0.3 (-0.92%)

18:38
05/20/18
05/20
18:38
05/20/18
18:38
Hot Stocks
Janus Henderson Group announces dividend of 36c »

Janus Henderson Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHG

Philips

$43.01

0.26 (0.61%)

17:29
05/20/18
05/20
17:29
05/20/18
17:29
Hot Stocks
New data shows combined COPD treatments could help reduce annual cost of care »

At the American Thoracic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$94.26

1.37 (1.47%)

, CMCSA

Comcast

$32.72

0.3 (0.93%)

16:45
05/20/18
05/20
16:45
05/20/18
16:45
Hot Stocks
Box Office Battle: 'Deadpool 2' debuts at number 1 with $125M »

Ryan Reynolds and…

TWX

Time Warner

$94.26

1.37 (1.47%)

CMCSA

Comcast

$32.72

0.3 (0.93%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$48.60

-0.2 (-0.41%)

FOX

21st Century Fox

$37.27

-0.01 (-0.03%)

FOXA

21st Century Fox

$37.67

-0.08 (-0.21%)

LGF.A

Lionsgate

$24.27

0.3 (1.25%)

DIS

Disney

$103.94

-0.4 (-0.38%)

VIAB

Viacom

$27.24

-0.92 (-3.27%)

VIA

Viacom

$33.80

-0.75 (-2.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

TSLA

Tesla

$276.84

-7.6 (-2.67%)

16:28
05/20/18
05/20
16:28
05/20/18
16:28
Periodicals
ISS recommending Tesla shareholders split chairman, CEO role, Bloomberg says »

The largest proxy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

, SPX

S&P 500

$0.00

(0.00%)

16:23
05/20/18
05/20
16:23
05/20/18
16:23
Periodicals
China agrees to import more from U.S., no sign of $200B target, Reuters says »

China has agreed to…

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$14.98

-0.05 (-0.33%)

, WAB

Wabtec

$95.23

1.1 (1.17%)

16:19
05/20/18
05/20
16:19
05/20/18
16:19
Periodicals
GE nearing deal to merge transportation unit with Wabtec, Reuters says »

General Electric (GE) is…

GE

General Electric

$14.98

-0.05 (-0.33%)

WAB

Wabtec

$95.23

1.1 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 12

    Jun

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

, SPX

S&P 500

$0.00

(0.00%)

16:17
05/20/18
05/20
16:17
05/20/18
16:17
Periodicals
Trump administration walks back Chinese tariff plans, Axios says »

Treasury Secretary Steve…

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDS

Dillard's

$77.47

0.965 (1.26%)

16:13
05/20/18
05/20
16:13
05/20/18
16:13
Hot Stocks
Dillard's announces 10c cash dividend »

Dillard's announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VCYT

Veracyte

$6.45

-0.07 (-1.07%)

16:11
05/20/18
05/20
16:11
05/20/18
16:11
Hot Stocks
Data shows 'real-world' value of Afirma GSC in thyroid cancer diagnosis »

Veracyte announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 12

    Jun

MCHP

Microchip

$92.80

-0.1865 (-0.20%)

, MSCC

Microsemi

$68.60

(0.00%)

15:42
05/20/18
05/20
15:42
05/20/18
15:42
Conference/Events
Microsemi to host special shareholder meeting »

Special shareholder…

MCHP

Microchip

$92.80

-0.1865 (-0.20%)

MSCC

Microsemi

$68.60

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HDNG

Hardinge

$18.44

0.03 (0.16%)

15:35
05/20/18
05/20
15:35
05/20/18
15:35
Conference/Events
Hardinge to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBRG

Bravo Brio Restaurant

$4.05

(0.00%)

15:30
05/20/18
05/20
15:30
05/20/18
15:30
Conference/Events
Bravo Brio Restaurant to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAYRY

Bayer

$0.00

(0.00%)

, BDX

Becton Dickinson

$225.01

0.81 (0.36%)

04:55
05/20/18
05/20
04:55
05/20/18
04:55
Conference/Events
American Thoracic Society to hold a conference »

ATS 2018 will be held in…

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$225.01

0.81 (0.36%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

BSX

Boston Scientific

$30.46

0.13 (0.43%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FGEN

FibroGen

$51.10

-0.2 (-0.39%)

GSK

GlaxoSmithKline

$40.04

-0.06 (-0.15%)

HRC

Hill-Rom

$90.58

0.86 (0.96%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

RETA

Reata Pharmaceuticals

$31.58

-0.59 (-1.83%)

OCX

OncoCyte

$2.55

0.05 (2.00%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

NBRV

Nabriva Therapeutics

$5.43

0.25 (4.83%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

MASI

Masimo

$97.11

0.34 (0.35%)

TEVA

Teva

$21.23

0.12 (0.57%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

REGN

Regeneron

$301.87

-6.26 (-2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 24

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 07

    Sep

  • 20

    Oct

  • 13

    Nov

  • 20

    Dec

CBS

CBS

$51.75

0.14 (0.27%)

, VIA

Viacom

$33.80

-0.75 (-2.17%)

13:23
05/19/18
05/19
13:23
05/19/18
13:23
Periodicals
CBS looks like a bargain, Barron's says »

In a follow-up story,…

CBS

CBS

$51.75

0.14 (0.27%)

VIA

Viacom

$33.80

-0.75 (-2.17%)

VIAB

Viacom

$27.24

-0.92 (-3.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$73.45

-0.51 (-0.69%)

, PEP

PepsiCo

$97.51

-0.45 (-0.46%)

13:10
05/19/18
05/19
13:10
05/19/18
13:10
Periodicals
Coca-Cola, PepsiCo look like bargains, Barron's says »

Investors have punished…

PG

Procter & Gamble

$73.45

-0.51 (-0.69%)

PEP

PepsiCo

$97.51

-0.45 (-0.46%)

KO

Coca-Cola

$42.18

-0.13 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$35.40

1.14 (3.33%)

10:32
05/19/18
05/19
10:32
05/19/18
10:32
Periodicals
Roku relevance worth taking note of, Barron's says »

Roku now is mostly a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

LOW

Lowe's

$86.31

0.85 (0.99%)

10:19
05/19/18
05/19
10:19
05/19/18
10:19
Periodicals
Lowe's turnaround what matters for long-term investors, Barron's says »

With Lowe's shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

AAPL

Apple

$186.31

-0.69 (-0.37%)

, ZTCOY

ZTE Corp.

$0.00

(0.00%)

08:41
05/19/18
05/19
08:41
05/19/18
08:41
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$186.31

-0.69 (-0.37%)

ZTCOY

ZTE Corp.

$0.00

(0.00%)

ACIA

Acacia Communications

$32.97

0.45 (1.38%)

OCLR

Oclaro

$8.88

-0.015 (-0.17%)

TOSBF

Toshiba, also use TOSYY

$0.00

(0.00%)

TOSYY

Toshiba, also use TOSBF

$0.00

(0.00%)

GM

General Motors

$37.80

-0.51 (-1.33%)

F

Ford

$11.33

-0.12 (-1.05%)

FCAU

Fiat Chrysler

$21.86

-0.31 (-1.40%)

HMC

Honda

$32.98

-0.11 (-0.33%)

TM

Toyota

$136.04

-0.54 (-0.40%)

NSANY

Nissan

$0.00

(0.00%)

VLKAY

Volkswagen

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

VRX

Valeant

$22.15

0.12 (0.54%)

PFE

Pfizer

$35.64

-0.07 (-0.20%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

INSY

Insys Therapeutics

$6.95

-0.37 (-5.05%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

BAYRY

Bayer

$0.00

(0.00%)

GILD

Gilead

$68.01

0.41 (0.61%)

BMRN

BioMarin

$88.95

0.51 (0.58%)

MNK

Mallinckrodt

$15.70

-0.37 (-2.30%)

SHPG

Shire

$169.62

-2.18 (-1.27%)

MRK

Merck

$59.13

0.06 (0.10%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

TEVA

Teva

$21.23

0.12 (0.57%)

AZN

AstraZeneca

$36.34

-0.09 (-0.25%)

ACOR

Acorda Therapeutics

$23.65

-0.45 (-1.87%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

NVS

Novartis

$77.08

-0.07 (-0.09%)

RHHBY

Roche

$0.00

(0.00%)

GALE

Galena

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 24

    May

  • 25

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 12

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

  • 22

    Aug

  • 27

    Aug

  • 07

    Sep

  • 10

    Sep

  • 12

    Sep

  • 05

    Oct

  • 23

    Oct

  • 13

    Nov

  • 20

    Dec

  • 21

    Dec

BAYRY

Bayer

$0.00

(0.00%)

, BDX

Becton Dickinson

$225.01

0.81 (0.36%)

04:55
05/19/18
05/19
04:55
05/19/18
04:55
Conference/Events
American Thoracic Society to hold a conference »

ATS 2018 will be held in…

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$225.01

0.81 (0.36%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

BSX

Boston Scientific

$30.46

0.13 (0.43%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FGEN

FibroGen

$51.10

-0.2 (-0.39%)

GSK

GlaxoSmithKline

$40.04

-0.06 (-0.15%)

HRC

Hill-Rom

$90.58

0.86 (0.96%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

RETA

Reata Pharmaceuticals

$31.58

-0.59 (-1.83%)

OCX

OncoCyte

$2.55

0.05 (2.00%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

NBRV

Nabriva Therapeutics

$5.43

0.25 (4.83%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

MASI

Masimo

$97.11

0.34 (0.35%)

TEVA

Teva

$21.23

0.12 (0.57%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

REGN

Regeneron

$301.87

-6.26 (-2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 24

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 07

    Sep

  • 20

    Oct

  • 13

    Nov

  • 20

    Dec

SLDB

Solid Biosciences

$21.96

-0.79 (-3.47%)

18:46
05/18/18
05/18
18:46
05/18/18
18:46
Hot Stocks
Solid Biosciences announces new preclinical data for SGT-001 »

Solid Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

, USO

United States Oil Fund

$14.43

-0.06 (-0.41%)

18:04
05/18/18
05/18
18:04
05/18/18
18:04
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 2.4K…

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

USO

United States Oil Fund

$14.43

-0.06 (-0.41%)

GLD

SPDR Gold Trust

$122.42

0.06 (0.05%)

FXE

Euro Currency Trust

$113.01

-0.28 (-0.25%)

FXC

CurrencyShares Canadian Dollar Trust

$76.61

-0.38 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$114.04

0.11 (0.10%)

18:02
05/18/18
05/18
18:02
05/18/18
18:02
Hot Stocks
Celanese raises prices for emulsion polymers and acetyls »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.